chuminhua04-04 09:44
4月1日，日前，Pharming公司公布了PI3Kδ抑制剂leniolisib治疗PI3Kδ激活综合征患者的关键性2/3期临床试验的最新数据。数据显示，这一试验达到了共同主要终点，缩小患者淋巴结病灶并增加幼稚B细胞比例。基于这些积极结果，该公司计划在今年第二季度递交监管申请。网页链接
| 今开：11.56 | 昨收：11.47 |
| 最高：11.56 | 最低：11.55 |
| 涨停价： | 跌停价： |
| 总市值：754190908 |
chuminhua04-04 09:44
4月1日，日前，Pharming公司公布了PI3Kδ抑制剂leniolisib治疗PI3Kδ激活综合征患者的关键性2/3期临床试验的最新数据。数据显示，这一试验达到了共同主要终点，缩小患者淋巴结病灶并增加幼稚B细胞比例。基于这些积极结果，该公司计划在今年第二季度递交监管申请。网页链接
产业链观察2021-07-01 21:00
药闻| 2021 年7月1 日，$Orchard Therapeutics(ORTX)$ 和$Pharming Group(PHAR)$ 宣布了一项战略合作，以研究、开发、制造和商业化 OTL-105，这是一种新披露的研究性离体自体造血干细胞 (HSC) 基因疗法，用于治疗遗传性血管性水肿 (HAE)，------ 一种威胁生命的罕见疾病，会导致面部、喉咙、四肢和...
Pharming Group(PHAR)08-02 18:12
$Pharming Group(PHAR)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001628280-22-020015 Act: 34 Size: 181 KB 网页链接
Pharming Group(PHAR)08-04 18:13
$Pharming Group(PHAR)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001628280-22-020806 Act: 34 Size: 637 KB 网页链接
Pharming Group(PHAR)08-01 18:12
$Pharming Group(PHAR)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001628280-22-019883 Act: 34 Size: 184 KB 网页链接
Pharming Group(PHAR)06-02 20:36
$Pharming Group(PHAR)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001628280-22-015969 Act: 34 Size: 168 KB 网页链接
Pharming Group(PHAR)05-19 01:03
$Pharming Group(PHAR)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001628280-22-014715 Act: 34 Size: 169 KB 网页链接
Pharming Group(PHAR)05-12 18:42
$Pharming Group(PHAR)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001628280-22-013943 Act: 34 Size: 323 KB 网页链接
Pharming Group(PHAR)05-05 18:51
$Pharming Group(PHAR)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001628280-22-012417 Act: 34 Size: 170 KB 网页链接
Pharming Group(PHAR)04-22 18:51
$Pharming Group(PHAR)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001628280-22-009964 Act: 34 Size: 171 KB 网页链接
Pharming Group(PHAR)08-04 18:13
$Pharming Group(PHAR)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001628280-22-020806 Act: 34 Size: 637 KB 网页链接查看全文
Pharming Group(PHAR)08-02 18:12
$Pharming Group(PHAR)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001628280-22-020015 Act: 34 Size: 181 KB 网页链接查看全文
Pharming Group(PHAR)08-01 18:12
$Pharming Group(PHAR)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001628280-22-019883 Act: 34 Size: 184 KB 网页链接查看全文
Pharming Group(PHAR)06-02 20:36
$Pharming Group(PHAR)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001628280-22-015969 Act: 34 Size: 168 KB 网页链接查看全文
Pharming Group(PHAR)05-19 01:03
$Pharming Group(PHAR)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001628280-22-014715 Act: 34 Size: 169 KB 网页链接查看全文
Pharming Group(PHAR)05-12 18:42
$Pharming Group(PHAR)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001628280-22-013943 Act: 34 Size: 323 KB 网页链接查看全文
Pharming Group(PHAR)05-05 18:51
$Pharming Group(PHAR)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001628280-22-012417 Act: 34 Size: 170 KB 网页链接查看全文
Pharming Group(PHAR)04-26 19:12
$Pharming Group(PHAR)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001628280-22-010179 Act: 34 Size: 182 KB 网页链接查看全文
Pharming Group(PHAR)04-22 18:51
$Pharming Group(PHAR)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001628280-22-009964 Act: 34 Size: 171 KB 网页链接查看全文
Pharming Group(PHAR)04-07 04:18
$Pharming Group(PHAR)$ 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Accession Number: 0001628280-22-008574 Act: 34 Size: 70 MB 网页链接查看全文
$Pharming Group(PHAR)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001628280-22-020806 Act: 34 Size: 637 KB 网页链接
$Pharming Group(PHAR)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001628280-22-020015 Act: 34 Size: 181 KB 网页链接
$Pharming Group(PHAR)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001628280-22-019883 Act: 34 Size: 184 KB 网页链接
$Pharming Group(PHAR)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001628280-22-015969 Act: 34 Size: 168 KB 网页链接
$Pharming Group(PHAR)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001628280-22-014715 Act: 34 Size: 169 KB 网页链接
$Pharming Group(PHAR)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001628280-22-013943 Act: 34 Size: 323 KB 网页链接
$Pharming Group(PHAR)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001628280-22-012417 Act: 34 Size: 170 KB 网页链接
$Pharming Group(PHAR)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001628280-22-010179 Act: 34 Size: 182 KB 网页链接
$Pharming Group(PHAR)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001628280-22-009964 Act: 34 Size: 171 KB 网页链接
$Pharming Group(PHAR)$ 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Accession Number: 0001628280-22-008574 Act: 34 Size: 70 MB 网页链接